pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,286 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT989Endpoints758BioPharma Dive291BioSpace196Fierce Biotech187onclive165globenewswire health73raps
therapy area
allOncology5794Rare Disease1330Cardiology1076Immunology975Hematology974Pulmonology878Vaccines
  • Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer
    Dr. Pedro Barata and Dr. Johann De Bono discuss the future direction of radiopharmaceutical therapies and emerging treatment strategies in metastatic castration-resistant prostate cancer (mCRPC).
    onclive · 3mo ago↗ source
  • Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer
    Dr. Johann De Bono and Dr. Pedro Barata discuss practical approaches to monitoring and managing toxicities associated with radiopharmaceutical therapies in metastatic castration-resistant prostate…
    onclive · 3mo ago↗ source
  • Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer
    Dr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castration-res…
← prev
page 39 of 52
next →
70
fda recalls44
fda medwatch33
fda press26
833
Psychiatry & CNS701
Ophthalmology410
Endocrinology & Metabolism357
Pain356
Infectious Disease343
onclive · 3mo ago↗ source
  • Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of treatment sequencing and patient selection for radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).
    onclive · 3mo ago↗ source
  • Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer
    Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics influence the use of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).
    onclive · 3mo ago↗ source
  • Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer
    Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus on radium…
    onclive · 3mo ago↗ source
  • Consensus Recommendations Address Key Controversies in Lymphoma Management
    Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.
    onclive · 3mo ago↗ source
  • Combination Radiopharmaceutical Approaches in Metastatic Castration-Resistant Prostate Cancer
    Dr. Pedro Barata and Dr. Johann De Bono discuss emerging combination strategies involving radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC), with a focus on the scient…
    onclive · 3mo ago↗ source
  • Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer
    Dr. Pedro Barata and Dr. Johann De Bono open the discussion by reviewing the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC) and outlining how these…
    onclive · 3mo ago↗ source
  • U.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changes
    About 70,000 Americans died of drug overdoses last year — about 14% fewer than the previous year, according to preliminary government data.
    STAT · 3mo ago↗ source
  • Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors
    Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors.
    onclive · 3mo ago↗ source
  • Medicare halts enrollment of new hospice, home health providers
    The Centers for Medicare and Medicaid Services said it will pause the enrollment of new hospice and home health providers.
    STAT · 3mo ago↗ source
  • Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD
    Peter Enzinger, MD, answers common questions about the diagnosis and management of esophageal cancer in this clinician-focused FAQ interview.
    onclive · 3mo ago↗ source
  • The ‘velocity of obesity’ aims to show which nations are slowing an epidemic
    A study finds the rise in U.S. obesity rates have hit a plateau in children but are still climbing for adults, and are still high compared to those in other…
    STAT · 3mo ago↗ source
  • FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD
    Luhua (Michael) Wang, MD, discusses the implications of the FDA approval of brexu-cel for the treatment of adult patients with relapsed/refractory MCL.
    onclive · 3mo ago↗ source
  • New subpoena suggests DOJ has begun criminal investigation of gender-affirming care
    Several hospitals have received federal grand jury subpoenas regarding gender-affirming care for minors, suggesting a criminal investigation has begun.
    STAT · 3mo ago↗ source
  • STAT+: Gene therapy viruses linked to a boy’s tumor
    The case for Makary as the WOAT, Cassidy's seat at risk ahead of midterms, and other biotech news from The Readout
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
    FDA Commissioner Marty Makary is resigning, and Kyle Diamantas, the agency's top food regulator, will step in as acting commissioner
    STAT · 3mo ago↗ source
  • STAT+: AI medical devices’ dirty FDA secret
    In this edition of STAT's AI Prognosis newsletter: A look at the quirks of the most common FDA medical device approval pathway, sepsis algorithms, and more.
    STAT · 3mo ago↗ source
  • UCSF Receives Major Gift to Advance Research and Modernization
    Kathy Chiao and Ken Hao commit $100 million for major capital projects, cancer research, and innovation at UCSF — building on a recent $75 million gift to UC Davis for veterinary medicine.
    onclive · 3mo ago↗ source
  • Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer
    The panel surveys the clinical trial landscape and emerging therapeutic strategies for patients with recurrent endometrial cancer, particularly those who have progressed on frontline checkpoint inh…
    onclive · 3mo ago↗ source
  • CLL-321 Trial Efficacy and Safety Results Analysis
    Phase 3 results: pirtobrutinib boosts PFS, delays next treatment after prior BTK therapy, and shows low cardiac toxicity.
    onclive · 3mo ago↗ source
  • How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCO
    Drs Camidge and Blanke discuss Dr Blanke's career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying.
    onclive · 3mo ago↗ source
  • BRUIN CLL-321 Trial Impact and Treatment Selection
    Experts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.
    onclive · 3mo ago↗ source
  • Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy
    Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.
    onclive · 3mo ago↗ source